Last updated: February 15, 2026
mmary
Cilofexor, an FXR (farnesoid X receptor) agonist, progresses through clinical development targeting nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). Its market potential hinges on successful Phase 2 and Phase 3 outcomes, regulatory approvals, and competitive landscape dynamics. Current data show promising efficacy signals, but risks remain regarding safety, endpoints achievement, and market adoption.
What is the current development stage of Cilofexor?
Cilofexor developed by Gilead Sciences is advancing through late-phase clinical trials with a focus on NASH.
- Phase 2 Trial (LIFT study): Completed in 2021, evaluated efficacy and tolerability in NASH patients.
- Phase 3 Trials: Under planning or early stages aiming for larger patient populations and extended endpoints. Exact start dates are undisclosed but anticipated within the next 12 months based on company statements from 2022–2023.
- Other indications: Testing in primary sclerosing cholangitis (PSC) remains investigational, with early-phase data available.
What are the key clinical data points for Cilofexor?
Efficacy
Regulatory Status
- No current FDA or EMA approvals.
- Gilead intends to submit Phase 3 protocols by late 2023 or early 2024, aiming for regulatory filings in 2026.
What are the competitive dynamics?
-
Key competitors:**
- Resmetirom (Midration): Phase 3 candidate with interim results showing 15–20% liver fat reduction.
- Vonafexor (Intercept Pharmaceuticals): Also FXR agonist, with mixed efficacy data and ongoing trials.
- Obeticholic acid (Intercept): Closest competitor, authorized in certain markets for primary biliary cholangitis, with late-stage NASH trials showing modest efficacy and safety concerns over long-term use.
-
Differentiation factors:
- Cilofexor shows promising early efficacy with fewer adverse events.
- Its specificity for FXR may lead to distinct metabolic and fibrotic benefits.
What market projections exist for Cilofexor?
Market size estimates (2023-2030)
Forecast assumptions
- Market penetration: Expect early adoption in specialized centers with efficacy data.
- Pricing: Oral FXR agonists generally priced between $10,000–$20,000 annually per patient.
-
Revenue potential:
- If Cilofexor gains approval and captures 10-15% of NASH submarket, projected global revenues could reach $1–2 billion annually by 2030.
- Market share depends on competitors' progress, regulatory decisions, and demonstrated long-term benefits.
What are the risks for Cilofexor’s market success?
- Efficacy: Critical to demonstrate histological improvements (fibrosis regression, NASH resolution) in Phase 3.
- Safety concerns: Persistent pruritus and other side effects could limit uptake.
- Regulatory hurdles: Meeting endpoints required by authorities, such as histology-based improvements, remains challenging.
- Market competition: Several candidates advancing, including Obeticholic acid and non-FXR drugs like lomitapide and selonsertib.
Key developments to watch
- Completion of Phase 3 trial enrollment, expected in 2024.
- Submission of New Drug Applications (NDAs) around late 2025 to early 2026.
- Long-term safety data, particularly regarding pruritus and lipid effects, will guide post-approval positioning.
Key Takeaways
- Cilofexor is in advanced clinical development targeting NASH, with initial efficacy signals showing promise.
- Its market potential depends heavily on Phase 3 success, safety profile, and competitive landscape.
- The global NASH market could generate billions annually, with early adoption expected among specialized physicians.
- Risks include unmet endpoints, safety concerns, and McKinsey-wild competition.
FAQs
1. When is Cilofexor expected to reach the market?
Pending successful Phase 3 trials and regulatory approval, Cilofexor may be launched around 2026–2027.
2. How does Cilofexor compare to Obeticholic acid?
Cilofexor shows comparable efficacy signals but appears to have a better safety profile, especially concerning pruritus, based on early data.
3. What is the primary indication for Cilofexor?
NASH with fibrosis is the primary focus; PSC remains investigative.
4. What markets are most promising for Cilofexor?
The U.S., Europe, and Japan, where NASH prevalence is high; emerging markets may follow.
5. What is the key challenge for Cilofexor’s commercial success?
Achieving regulatory approval by demonstrating clear histological benefits and managing safety concerns.
Sources:
[1] Gilead Sciences Clinical Trial Registry (2023).
[2] Bloomberg New Pharma Market Estimates (2023).
[3] Global Liver Disease Market Report (2022).
[4] Company Press Releases and Regulatory Filings (2023).
